Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Cyprus: These 21 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Cyprus: These 21 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Cyprus?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Cyprus Patent 1,115,088

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Cyprus?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Cyprus Patent 1,113,594

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Cyprus?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Cyprus Patent 1,115,898

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Cyprus?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Cyprus Patent 2,015,043

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Cyprus?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Cyprus Patent 1,116,597

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Cyprus?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Cyprus Patent 2,016,017

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Cyprus?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Cyprus Patent 1,121,135

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Cyprus?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Cyprus Patent 1,111,264

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Cyprus?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Cyprus Patent 1,117,482

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Cyprus?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Cyprus Patent 2,020,032

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can INLYTA (axitinib) generic drug versions launch in Cyprus?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Cyprus Patent 1,119,119

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Cyprus?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Cyprus Patent 1,117,284

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Cyprus?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Cyprus Patent 1,118,434

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Cyprus?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Cyprus Patent 1,120,891

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Cyprus?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Cyprus Patent 1,118,434

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Cyprus?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Cyprus Patent 1,120,891

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Cyprus?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Cyprus Patent 1,115,145

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Cyprus?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Cyprus Patent 1,117,693

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Cyprus?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Cyprus Patent 1,121,338

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Cyprus?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Cyprus Patent 1,116,700

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Cyprus?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Cyprus Patent 1,115,619

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Cyprus?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Cyprus Patent 1,113,137

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Cyprus?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Cyprus Patent 1,118,498

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Cyprus?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Cyprus Patent 2,022,017

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Cyprus?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Cyprus Patent 1,118,496

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Cyprus?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Cyprus Patent 1,121,230

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Cyprus?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Cyprus Patent 1,125,300

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Cyprus?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Cyprus Patent 2,019,010

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Cyprus?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Cyprus Patent 2,019,010

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Cyprus?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Cyprus Patent 2,020,030

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Cyprus?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Cyprus Patent 1,124,103

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Cyprus Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks, and Commercial Outlook

Last updated: October 17, 2026

Cyprus is a small but strategically relevant EU pharmaceutical market. Demand is shaped by the national General Healthcare System (GHS), centralized reimbursement decisions, hospital procurement, external reference pricing, and heavy reliance on imported medicines. Branded products retain value in patented, hospital, specialty, and originator-led therapeutic segments. Generics have stronger access in chronic primary-care markets where reimbursement, prescribing controls, and price competition dominate.

The main commercial opportunity is market access through GHS reimbursement, hospital tenders, generic substitution, biosimilar adoption, and EU-wide regulatory procedures. The main challenges are limited market scale, price erosion, public procurement concentration, parallel trade, payment and tender execution risk, and the need to comply with Cyprus-specific pricing and reimbursement procedures.

How large is the Cyprus pharmaceutical market?

Cyprus is a small-volume market with a population of approximately 923,000 in the areas under the effective control of the Republic of Cyprus, based on the 2021 census (Statistical Service of Cyprus, 2023). The market is commercially attractive for products with high unit value, differentiated clinical positioning, or regional distribution potential, but it is less attractive for low-margin products requiring large sales forces.

Cyprus has several structural characteristics:

Market factor Commercial effect
Small resident population Limits absolute sales volume and reduces the return on local infrastructure
High imported-medicine dependence Creates opportunities for distributors, EU manufacturers, and parallel suppliers
GHS reimbursement Concentrates payer access around Health Insurance Organisation rules
Public hospital procurement Creates tender-driven volume opportunities
EU membership Enables EU regulatory procedures and European patent protection
Tourism and expatriate population Supports demand across acute, chronic, and specialty therapies
Separate political administration in the north Creates a distinct legal and regulatory environment outside the Republic of Cyprus system

The northern part of the island is outside the effective control of the Republic of Cyprus. EU law is suspended in that area under Protocol No. 10 of the 2003 Act of Accession. A market assessment for the Republic of Cyprus should not treat the north as part of the same regulated pharmaceutical market (European Union, 2003).

How is the Cyprus branded drug market structured?

Branded medicines remain strongest in patented products, hospital medicines, specialty care, oncology, rare diseases, advanced therapies, and products with limited therapeutic substitution. Originator products also retain commercial positions where physicians value established clinical evidence, supply reliability, device familiarity, or a narrow therapeutic index.

The GHS has altered the commercial model. Access depends less on traditional private-sector promotion alone and more on reimbursement status, prescribing behavior, patient co-payment, therapeutic-category rules, and product availability through contracted providers.

What are the main branded-drug opportunities?

Branded manufacturers have the strongest opportunities in:

  • Oncology and hematology
  • Immunology and rheumatology
  • Diabetes and obesity therapies
  • Cardiovascular disease
  • Neurology and psychiatry
  • Rare diseases
  • Hospital anti-infectives
  • Vaccines
  • Specialty injectables
  • Biosimilars and reference biologics
  • Products with pediatric or orphan-drug positioning

Centralized European authorization can reduce regulatory duplication. Products subject to mandatory centralized authorization must use the European Medicines Agency pathway, while other products may use national, decentralized, or mutual-recognition procedures under EU pharmaceutical law (European Parliament and Council, 2001; European Medicines Agency, 2024).

For branded products, the principal commercial risk is rapid loss of volume after generic or biosimilar entry. A Cyprus launch strategy therefore needs to coordinate regulatory approval, GHS reimbursement, supply continuity, local distribution, and lifecycle management before loss of exclusivity.

How competitive is the Cyprus generic drug market?

Generics are structurally important because Cyprus relies heavily on imported medicines and uses reimbursement controls to manage public expenditure. Generic companies compete on price, availability, wholesaler relationships, tender execution, and physician or pharmacist acceptance.

The strongest generic opportunities are in:

  • Chronic cardiovascular treatment
  • Diabetes
  • Respiratory disease
  • Gastroenterology
  • Anti-infectives
  • Pain management
  • Central nervous system medicines
  • Hospital injectables
  • High-volume off-patent medicines
  • Products with supply shortages or limited incumbent competition

Generic entry is generally easier when a product has:

  1. Expired regulatory exclusivity;
  2. No enforceable Cyprus patent or supplementary protection certificate;
  3. A clear reference product;
  4. Established EU manufacturing capacity;
  5. A reimbursement price that supports import and distribution costs;
  6. Reliable supply to pharmacies and hospitals.

Cyprus is not a US-style Orange Book jurisdiction. There is no single national Orange Book that performs the same patent-listing function as the U.S. Food and Drug Administration publication. Regulatory approval, national marketing authorization records, the European Medicines Agency database, and patent-register information must be assessed separately. A company should not assume that an EU marketing authorization confirms freedom to operate in Cyprus.

What is the regulatory pathway for branded and generic medicines?

Cyprus applies EU pharmaceutical rules through the Pharmaceutical Services of the Ministry of Health and the national competent-authority framework. Products may reach Cyprus through:

Route Typical use
Centralized procedure Oncology, biologics, advanced therapies, orphan medicines, and other mandatory categories
Decentralized procedure New products seeking authorization in several EU countries
Mutual-recognition procedure Reliance on an existing national authorization
National procedure Products marketed only in Cyprus or in limited circumstances
Generic application Article 10 pathway based on a reference medicinal product
Hybrid application Products with differences from the reference product requiring supporting data
Well-established-use application Products supported by established medical use and literature

EU law generally provides eight years of regulatory data exclusivity, followed by two years of market protection, with a possible additional year for a significant new therapeutic indication under the “8+2+1” framework (European Parliament and Council, 2001). Patent protection operates separately from regulatory exclusivity.

A generic authorization does not eliminate patent risk. An applicant must assess Cyprus-valid European patents, national patents, supplementary protection certificates, pediatric extensions, formulation claims, manufacturing claims, and method-of-use claims before commercial launch.

What is the Orange Book status of medicines in Cyprus?

Cyprus has no direct equivalent to the U.S. Orange Book listing system. Patent and generic-launch analysis requires a document-based review across several sources:

  • Cyprus marketing authorization and product information;
  • EMA EPARs for centrally authorized products;
  • Cyprus national authorization records;
  • European Patent Office registers;
  • Cyprus patent validation records;
  • Supplementary protection certificate records;
  • National court decisions;
  • GHS reimbursement and product lists;
  • Hospital tender documents.

The absence of an Orange Book-style patent declaration system creates a practical due-diligence burden. A generic applicant must independently identify potentially relevant patents and determine whether a “skinny label,” carve-out, launch-at-risk, or patent challenge strategy is commercially viable.

When do branded drugs lose exclusivity in Cyprus?

Loss of exclusivity depends on four separate dates:

Exclusivity type Typical duration or endpoint
Patent 20 years from the filing date, subject to validity and scope
Supplementary protection certificate Up to five additional years after patent expiry
Pediatric extension Up to six additional months in qualifying cases
Regulatory data protection Eight years
Market protection Two years after data protection
New indication protection Potential additional one year

The relevant commercial date is the earliest point at which a lawful competitor can obtain authorization, secure reimbursement, and enter the market. Patent expiry alone does not guarantee immediate generic launch. Conversely, regulatory exclusivity may expire before a patent or SPC.

What patents protect branded medicines in Cyprus?

The main patent categories are:

  • Composition-of-matter claims;
  • Salt, polymorph, crystalline-form, and stereochemical claims;
  • Formulation and controlled-release claims;
  • Device and administration-system claims;
  • Dosage-regimen claims;
  • Patient-selection claims;
  • Combination-treatment claims;
  • Manufacturing-process claims;
  • Intermediate and purification claims.

European patents validated in Cyprus can create enforceable rights in the country. Cyprus is part of the European patent system, but the European Patent Office grant does not create a unitary patent for Cyprus unless the applicable territorial and legal requirements are satisfied. Cyprus should therefore be analyzed as a national validation jurisdiction.

What Paragraph IV challenges and generic litigation risks exist?

Cyprus does not operate the U.S. Hatch-Waxman Paragraph IV system. A Cyprus generic applicant does not file a U.S.-style Paragraph IV certification with the Cyprus authority.

The functional equivalent is a patent challenge or non-infringement strategy based on:

  • Invalidity;
  • Lack of infringement;
  • Non-enforceability;
  • Patent expiry;
  • Absence of a valid SPC;
  • Non-infringing formulation;
  • Carved-out method of use;
  • Manufacturing outside the scope of the claims.

A generic company can also launch after expiry while preserving a challenge in another European jurisdiction. Litigation may be brought in Cyprus where the relevant patent is enforceable and the alleged conduct occurs. Cyprus does not currently operate as a Unified Patent Court local-divisional venue. European patent litigation strategy must account for the national status of the patent and the jurisdiction of any broader European proceedings.

How does a Cyprus patent challenge differ from a U.S. Paragraph IV case?

Issue Cyprus United States
Patent listing No direct Orange Book equivalent FDA Orange Book listing
Certification No Hatch-Waxman Paragraph IV certification Paragraph I-IV certifications
Litigation trigger National infringement or invalidity action Notice letter and statutory litigation framework
Patent scope Cyprus-valid European or national rights U.S. patents
Regulatory authority Cyprus and EU framework FDA
Market effect National launch and injunction risk 30-month stay may apply

The absence of a formal Paragraph IV pathway reduces procedural standardization. It does not remove patent litigation risk.

How are medicines priced and reimbursed in Cyprus?

The Ministry of Health and Pharmaceutical Services regulate medicinal products, while the Health Insurance Organisation administers the GHS. Reimbursement and prescribing decisions are affected by therapeutic protocols, product availability, reference pricing, co-payments, and formulary treatment (Health Insurance Organisation, 2024).

What matters for GHS reimbursement?

Manufacturers must manage:

  • National price approval;
  • Reimbursement-list inclusion;
  • Therapeutic-category placement;
  • Reference-product and generic pricing;
  • Physician prescribing controls;
  • Patient co-payment;
  • Pharmacy dispensing rules;
  • Supply obligations;
  • Hospital and public-sector tenders;
  • Pharmacovigilance and shortage reporting.

A product can hold a marketing authorization without achieving meaningful commercial access. Reimbursement listing and supply performance determine whether authorization converts into sales.

For branded products, reimbursement negotiations should begin before regulatory approval where possible. For generics, the commercial plan should model the approved price, wholesaler margin, pharmacy economics, tender discounts, import costs, and the impact of subsequent entrants.

What biosimilar risks and opportunities exist in Cyprus?

Biosimilars authorized through the EU system can enter Cyprus after the relevant reference-product protections expire. The regulatory pathway depends on EMA or applicable national procedures, but commercial uptake remains a national market-access issue.

Biosimilar opportunities are strongest in high-cost biologic categories, including oncology, autoimmune disease, diabetes, and supportive care. Risks include:

  • Physician reluctance to switch stable patients;
  • Hospital tender concentration;
  • Originator rebate strategies;
  • Supply interruptions;
  • Limited local clinical education;
  • Substitution rules that differ by product and setting;
  • Price compression after multiple entrants.

Cyprus can be attractive for biosimilars with reliable supply, competitive tender pricing, and a strong medical-affairs strategy. The market is too small to support a standalone commercial infrastructure for many products, so regional models using Greece, Malta, or broader Southeast European operations can improve economics.

Which companies are challenging the Cyprus market?

The competitive landscape includes four groups:

  1. Multinational originators with patented and specialty products;
  2. European generic and biosimilar manufacturers;
  3. Local marketing authorization holders and distributors;
  4. Wholesalers supplying pharmacies, private hospitals, and public institutions.

The market is generally distributor-led. Local partners provide regulatory submissions, pharmacovigilance, tenders, wholesaler access, and relationships with pharmacies and healthcare providers. A foreign manufacturer can enter through a local representative or establish a direct subsidiary, but the latter is harder to justify for low-volume products.

What licensing deals are commercially relevant?

Licensing and distribution transactions are most useful for:

  • Generics without a local commercial platform;
  • Biosimilars requiring tender access;
  • Specialty medicines needing medical-affairs support;
  • Hospital products requiring procurement expertise;
  • Products with regional EU authorization but no Cyprus launch;
  • Out-licensing of Cyprus rights to local marketing authorization holders.

Deal terms should address GHS reimbursement responsibility, minimum supply commitments, tender participation, pharmacovigilance, recalls, serialization, parallel export controls, pricing approvals, and ownership of local regulatory data.

What manufacturing and intellectual-property barriers exist?

Cyprus has limited domestic pharmaceutical manufacturing relative to larger EU markets. Most commercial supply is imported. The key manufacturing barriers are therefore external:

  • EU good manufacturing practice compliance;
  • Qualified-person requirements;
  • Batch release;
  • Serialization under the Falsified Medicines Directive;
  • Cold-chain control;
  • Stability and packaging requirements;
  • Shortage-management obligations;
  • Dependence on a limited number of approved manufacturing sites.

Manufacturing-process patents can affect an imported generic even where the active ingredient patent has expired. Companies should review process claims, polymorph claims, formulation patents, and manufacturing-site declarations before shipment.

What generic launch scenarios exist in Cyprus?

Scenario 1: Immediate post-exclusivity launch

This is the lowest-risk scenario when regulatory exclusivity and Cyprus-valid patent rights have expired. Multiple generic suppliers may enter quickly, causing price erosion and limited margin.

Scenario 2: Limited-entry launch

A manufacturer enters with a narrow label, constrained indication, or differentiated formulation. This can reduce infringement risk but may limit reimbursement and prescribing access.

Scenario 3: Patent challenge

The company launches after an invalidity or non-infringement assessment and accepts litigation risk. This strategy is more suitable for high-value products with substantial post-entry revenue.

Scenario 4: Tender-led launch

The product enters through public hospital or institutional procurement. Volume may be substantial relative to market size, but margins depend on tender pricing and contract execution.

Scenario 5: Distributor-first launch

A local partner obtains reimbursement and manages supply. This reduces fixed costs but transfers commercial control and may reduce transparency over demand, inventory, and tender pricing.

How strong is the Cyprus pharmaceutical patent estate?

Cyprus patent estates are usually strongest where a product has:

  • A valid composition patent;
  • A live SPC;
  • Multiple formulation or polymorph patents;
  • A device patent;
  • Several approved indications;
  • Manufacturing-process claims;
  • Broad European family coverage.

They are weaker where:

  • The basic patent has expired;
  • Secondary patents have narrow claims;
  • The product relies on a single formulation patent;
  • The relevant indication can be carved out;
  • No Cyprus validation exists;
  • The patent has faced adverse validity findings elsewhere.

Patent strength should be scored separately from commercial strength. A strong patent may still produce limited Cyprus revenue because the market is small. A weak patent may still delay entry if litigation costs, injunction risk, and distributor commitments discourage challengers.

What is the outlook for Cyprus branded and generic medicines?

Cyprus is best viewed as a selective EU access market rather than a large standalone growth market. Branded companies should prioritize reimbursed specialty products, hospital medicines, and high-cost biologics. Generic companies should prioritize supply reliability, low operating cost, tender access, and rapid GHS integration.

The most defensible commercial strategy combines:

  • EU-level regulatory authorization;
  • Early Cyprus pricing preparation;
  • A capable local distributor;
  • GHS reimbursement planning;
  • Patent and SPC clearance;
  • Hospital tender monitoring;
  • Shortage-resistant supply;
  • Regional operating leverage.

Key Takeaways

  • Cyprus is a small, import-dependent EU pharmaceutical market.
  • The GHS is the central commercial gateway for reimbursed medicines.
  • Generics compete mainly through price, availability, reimbursement, and tenders.
  • Cyprus has no U.S.-style Orange Book or Paragraph IV procedure.
  • Patent analysis must cover European patents validated in Cyprus, SPCs, formulation claims, method-of-use claims, and manufacturing claims.
  • Biosimilars have opportunities in high-cost therapeutic areas, but uptake depends on local prescribing and procurement rules.
  • Local distributors remain important for reimbursement, pharmacovigilance, tenders, and supply.
  • Public procurement can create volume but increases price and execution pressure.
  • Cyprus is more attractive as part of a regional EU launch platform than as a standalone commercial operation.

FAQs

Does Cyprus recognize European Medicines Agency approvals?

Yes. Centrally authorized medicines can be marketed in Cyprus under the EU centralized procedure. National, decentralized, and mutual-recognition procedures may apply to products outside mandatory centralized categories.

Can a generic launch in Cyprus before a European patent expires?

Only if the launch does not infringe a valid Cyprus-enforceable right, or if the relevant patent or SPC is invalid, expired, not validated, or otherwise inapplicable. Marketing authorization does not resolve patent infringement.

Are biosimilars automatically substituted for biologics in Cyprus?

Substitution depends on the applicable product, prescribing environment, reimbursement rules, and national practice. Automatic substitution should not be assumed from EMA approval alone.

Does Cyprus have a national patent opposition system for medicines?

Patent validity and infringement disputes are handled through applicable Cyprus and European patent mechanisms. Cyprus does not replicate the U.S. Paragraph IV framework.

Is Cyprus attractive for a generic manufacturer without a local subsidiary?

Yes, particularly through a local marketing authorization holder, distributor, or regional partner. The economics are strongest where the product has GHS reimbursement, hospital demand, limited competition, or a high-value specialty indication.

References

  1. European Medicines Agency. (2024). Human medicines: Regulatory procedures and authorisation. https://www.ema.europa.eu/

  2. European Parliament and Council. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Communities.

  3. European Union. (2003). Act concerning the conditions of accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic and the adjustments to the Treaties on which the European Union is founded, Protocol No. 10 on Cyprus. Official Journal of the European Union.

  4. Health Insurance Organisation. (2024). General Healthcare System: Beneficiaries, providers, medicines and reimbursement. https://www.gesy.org.cy/

  5. Statistical Service of Cyprus. (2023). Demographic statistics and population census 2021. Ministry of Finance, Republic of Cyprus. https://www.cystat.gov.cy/

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.